Sareum Hldgs Plc (LSE:SAR) — Market Cap & Net Worth
Market Cap & Net Worth: Sareum Hldgs Plc (SAR)
Sareum Hldgs Plc (LSE:SAR) has a market capitalization of $497.35K (GBX4.09 Billion) as of September 17, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31066 globally and #928 in its home market, demonstrating a -7.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sareum Hldgs Plc's stock price GBX29.50 by its total outstanding shares 138565173 (138.57 Million). Also see balance sheet size of Sareum Hldgs Plc for a full breakdown of the balance sheet.
Sareum Hldgs Plc Market Cap History: 2015 to 2026
Sareum Hldgs Plc's market capitalization history from 2015 to 2026. Data shows growth from $155.95K to $497.35K (8.80% CAGR). Also see SAR cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Sareum Hldgs Plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$902.54 Million | 0.06% | #228 of 722 |
Weight: Sareum Hldgs Plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sareum Hldgs Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sareum Hldgs Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Sareum Hldgs Plc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
43.31x
Sareum Hldgs Plc's market cap is 43.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $2.04 Million | $47.20K | -$985.91K | 43.31x | N/A |
Competitor Companies of SAR by Market Capitalization
Companies near Sareum Hldgs Plc in the global market cap rankings as of September 17, 2026. Review tangible equity quality of Sareum Hldgs Plc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Sareum Hldgs Plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Sareum Hldgs Plc Historical Marketcap From 2015 to 2026
Between 2015 and today, Sareum Hldgs Plc's market cap moved from $155.95K to $ 497.35K, with a yearly change of 8.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX497.35K | +96.67% |
| 2025 | GBX252.89K | -38.78% |
| 2024 | GBX413.05K | -58.82% |
| 2023 | GBX1.00 Million | -27.88% |
| 2022 | GBX1.39 Million | -66.33% |
| 2021 | GBX4.13 Million | +102.06% |
| 2020 | GBX2.04 Million | +583.10% |
| 2019 | GBX299.25K | -32.38% |
| 2018 | GBX442.56K | -38.24% |
| 2017 | GBX716.52K | +13.33% |
| 2016 | GBX632.23K | +305.41% |
| 2015 | GBX155.95K | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Sareum Hldgs Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $497.35K USD |
| MoneyControl | $497.35K USD |
| MarketWatch | $497.35K USD |
| marketcap.company | $497.35K USD |
| Reuters | $497.35K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sareum Hldgs Plc
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical st… Read more